Viking Therapeutics Inc
North American company
News & analysis
Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.
Latest VKTX News